Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.92 |
| ▸ | EED | O75530 | 1/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.92 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.92 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.92 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.92 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.92 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.92 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.92 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13277447 | 0.99 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL18715336 | 0.98 | EZH2 (0.95) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13276848 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29350231 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL15313373 | 0.95 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13277005 | 0.95 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29361941 | 0.95 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL16653521 | 0.95 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087432 | 0.94 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276853 | 0.94 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4309738-A2 | METHOD OF TREATING MEDULLOBLASTOMA WITH AN EZH2 INHIBITOR | Epizyme Inc (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4252851-A2 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | Epizyme Inc (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3486234-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210121470-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY (MRTO)/SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE(SCCOHT) WITH AN EZH2 INHIBITOR | Epizyme, Inc. | 2021-04-29 | — | — | US | disclosed |
| EP-3659606-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190240230-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-20190175604-A1 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | Epizyme, Inc. | 2019-06-13 | — | — | US | disclosed |
| EP-3486234-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20180071300-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20170305889-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2017-10-26 | — | — | US | disclosed |
| EP-3150580-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121470-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY (MRTO)/SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE(SCCOHT) WITH AN EZH2 INHIBITOR | EZH2, KMT2A, EHMT2 | EZH2 1/4885NR1I2 1801/4885EED 145/4885 |
| US-20190240230-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885NR1I2 2613/4885EED 22/4885 |
| US-20190175604-A1 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | EZH2, DOT1L, BMI1 | EZH2 1/4885NR1I2 1950/4885EED 22/4885 |
| US-20170305889-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885NR1I2 2699/4885EED 16/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | EZH2 2/4885NR1I2 1955/4885EED 52/4885 |
| US-20180071300-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885NR1I2 2613/4885EED 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.